EP3710485B8 - Anti-sez6 antibody drug conjugates and methods of use - Google Patents

Anti-sez6 antibody drug conjugates and methods of use Download PDF

Info

Publication number
EP3710485B8
EP3710485B8 EP19732174.8A EP19732174A EP3710485B8 EP 3710485 B8 EP3710485 B8 EP 3710485B8 EP 19732174 A EP19732174 A EP 19732174A EP 3710485 B8 EP3710485 B8 EP 3710485B8
Authority
EP
European Patent Office
Prior art keywords
methods
drug conjugates
antibody drug
sez6 antibody
sez6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19732174.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3710485B1 (en
EP3710485A1 (en
Inventor
David Liu
Julia Gavrilyuk
Alexander SCHAMMEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Stemcentrx LLC
Original Assignee
AbbVie Stemcentrx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Stemcentrx LLC filed Critical AbbVie Stemcentrx LLC
Priority to SI201930050T priority Critical patent/SI3710485T1/sl
Priority to RS20210516A priority patent/RS61770B1/sr
Priority to PL19732174T priority patent/PL3710485T3/pl
Priority to EP21157876.0A priority patent/EP3858863A1/en
Publication of EP3710485A1 publication Critical patent/EP3710485A1/en
Application granted granted Critical
Publication of EP3710485B1 publication Critical patent/EP3710485B1/en
Priority to HRP20210631TT priority patent/HRP20210631T1/hr
Publication of EP3710485B8 publication Critical patent/EP3710485B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19732174.8A 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use Active EP3710485B8 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SI201930050T SI3710485T1 (sl) 2018-05-30 2019-05-30 Konjugati protitelo proti-SEZ6-zdravilo in postopki uporabe
RS20210516A RS61770B1 (sr) 2018-05-30 2019-05-30 Konjugati anti-sez6 antitela i leka i metodi primene
PL19732174T PL3710485T3 (pl) 2018-05-30 2019-05-30 Koniugaty lek-przeciwciaƂo anty-sez6 i sposoby ich stosowania
EP21157876.0A EP3858863A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use
HRP20210631TT HRP20210631T1 (hr) 2018-05-30 2021-04-21 Konjugati protutijela protiv sez6 s lijekom i postupci upotrebe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678061P 2018-05-30 2018-05-30
PCT/US2019/034701 WO2019232241A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21157876.0A Division-Into EP3858863A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use
EP21157876.0A Division EP3858863A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Publications (3)

Publication Number Publication Date
EP3710485A1 EP3710485A1 (en) 2020-09-23
EP3710485B1 EP3710485B1 (en) 2021-03-31
EP3710485B8 true EP3710485B8 (en) 2021-06-23

Family

ID=66998493

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21157876.0A Withdrawn EP3858863A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use
EP19732174.8A Active EP3710485B8 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21157876.0A Withdrawn EP3858863A1 (en) 2018-05-30 2019-05-30 Anti-sez6 antibody drug conjugates and methods of use

Country Status (31)

Country Link
US (3) US20210196834A1 (es)
EP (2) EP3858863A1 (es)
JP (1) JP6936399B2 (es)
KR (1) KR20210018316A (es)
CN (1) CN112135843A (es)
AU (1) AU2019278870A1 (es)
BR (1) BR112020024223A2 (es)
CA (1) CA3097199A1 (es)
CL (1) CL2020003044A1 (es)
CO (1) CO2020016151A2 (es)
CR (1) CR20200623A (es)
CY (1) CY1124183T1 (es)
DK (1) DK3710485T3 (es)
EC (1) ECSP20082970A (es)
ES (1) ES2867148T3 (es)
HR (1) HRP20210631T1 (es)
HU (1) HUE053616T2 (es)
IL (1) IL278225A (es)
LT (1) LT3710485T (es)
MA (1) MA51453A (es)
MX (1) MX2020012788A (es)
NZ (1) NZ768778A (es)
PE (1) PE20211497A1 (es)
PH (1) PH12020551968A1 (es)
PL (1) PL3710485T3 (es)
PT (1) PT3710485T (es)
RS (1) RS61770B1 (es)
RU (1) RU2770474C1 (es)
SG (1) SG11202011576VA (es)
SI (1) SI3710485T1 (es)
WO (1) WO2019232241A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152951A (ko) 2021-05-10 2022-11-17 강원대학ꔐ산학협렄닚 항ìČŽ êČ°í•© ìžŹìĄ°í•© 윔합 닚백질 및 읎넌 읎용한 항ìČŽ-ì•œëŹŒ 접합ìČŽ
KR20240029723A (ko) * 2022-08-26 2024-03-06 애람ëč„ ìžìœ”íŹë ˆìŽí‹°ë“œ 항-sez6 항ìČŽ ì•œëŹŒ 접합ìČŽ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1507556T (pt) * 2002-05-02 2016-09-28 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
JP6327855B2 (ja) 2010-09-03 2018-05-23 ă‚ąăƒƒăƒŽă‚Łăƒ»ă‚čăƒ†ăƒ ă‚»ăƒłăƒˆăƒ«ă‚Żă‚čăƒ»ă‚šăƒ«ăƒ»ă‚šăƒ«ăƒ»ă‚·ăƒŒ æ–°èŠăƒąă‚žăƒ„ăƒŹăƒŒă‚żćŠăłăăźäœżç”šæł•
PE20150091A1 (es) * 2012-02-24 2015-02-16 Stem Centrx Inc Anticuerpos anti-sez6 y metodos de empleo
US11432900B2 (en) 2013-07-03 2022-09-06 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
EP3038634A4 (en) * 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
RU2016111131A (ru) * 2013-08-28 2017-10-03 ЭББВИ СбЕМСЕНбРКС ЭлЭлХО ĐĄĐżĐŸŃĐŸĐ±Ń‹ ĐșĐŸĐœŃŠŃŽĐłĐ°Ń†ĐžĐž саĐčт-спДцОфОчДсĐșох Đ°ĐœŃ‚ĐžŃ‚Đ”Đ» Đž ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžĐž
MA41645A (fr) * 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
BR112017022682A2 (pt) * 2015-04-21 2018-07-10 Abbvie Stemcentrx Llc construçÔes de caliqueamicina e métodos de uso
WO2017112803A1 (en) * 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-mmp16 antibodies and methods of use
CN109563167A (zh) * 2016-06-08 2019-04-02 è‰ŸäŒŻç»Žć…Źćž 抗b7-h3æŠ—äœ“ć’ŒæŠ—äœ“èŻç‰©ć¶è”ç‰©

Also Published As

Publication number Publication date
BR112020024223A2 (pt) 2021-03-16
CN112135843A (zh) 2020-12-25
US20210196834A1 (en) 2021-07-01
RS61770B1 (sr) 2021-05-31
CL2020003044A1 (es) 2021-04-16
KR20210018316A (ko) 2021-02-17
HUE053616T2 (hu) 2021-07-28
CA3097199A1 (en) 2019-12-05
HRP20210631T1 (hr) 2021-05-28
PT3710485T (pt) 2021-05-04
US11077203B2 (en) 2021-08-03
ECSP20082970A (es) 2021-01-29
CO2020016151A2 (es) 2021-05-31
MA51453A (fr) 2020-09-23
CR20200623A (es) 2021-07-01
PH12020551968A1 (en) 2021-09-13
CY1124183T1 (el) 2022-05-27
US20210338831A1 (en) 2021-11-04
WO2019232241A1 (en) 2019-12-05
JP2021508694A (ja) 2021-03-11
RU2770474C1 (ru) 2022-04-18
SI3710485T1 (sl) 2021-08-31
SG11202011576VA (en) 2020-12-30
LT3710485T (lt) 2021-05-10
MX2020012788A (es) 2021-02-15
US20200316215A1 (en) 2020-10-08
ES2867148T3 (es) 2021-10-20
NZ768778A (en) 2022-07-01
PL3710485T3 (pl) 2021-09-13
EP3858863A1 (en) 2021-08-04
PE20211497A1 (es) 2021-08-11
IL278225A (en) 2020-11-30
JP6936399B2 (ja) 2021-09-15
AU2019278870A1 (en) 2020-10-29
DK3710485T3 (da) 2021-05-10
EP3710485B1 (en) 2021-03-31
EP3710485A1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
EP3706803A4 (en) CONJUGATES OF BIOMOLECULES AND THEIR USES
EP3337517A4 (en) ANTI-DLL3 ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
EP3580239A4 (en) ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
EP3852805A4 (en) ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF
EP3638697A4 (en) ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
EP3612567A4 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
EP3691692B8 (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
EP3842070A4 (en) MEDICATED COMBINATION OF QUINOLINE DERIVATIVE AND ANTIBODY
EP3972647A4 (en) DRUG CONJUGATES AND METHODS OF USE
EP3930756A4 (en) ANTIBODIES BINDING TO LILRB4 AND METHODS OF USE
EP3559043A4 (en) ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY ACTIVE CONJUGATES
EP4037715A4 (en) PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE
EP3836971A4 (en) CONJUGATES AND METHODS OF USE THEREOF
EP3579860A4 (en) ANTI-TRAILSHORT ANTIBODIES AND METHODS OF USE
EP3892639A4 (en) CD3 ANTIBODIES AND ITS PHARMACEUTICAL USE
IL283522A (en) Pharmaceutical preparations containing anti-191p4d12 antibody drug conjugates and methods of using them
IL286483A (en) Claudin-6 antibodies and drug conjugates
EP3601360A4 (en) ANTI-TMEFF1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
EP3890721A4 (en) MONOMETHYL FUMARATE AND CARRIER CONJUGATES AND METHODS OF USE THEREOF
EP3448885A4 (en) ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
EP3746484A4 (en) ANTI-MS4A6A ANTIBODIES AND PROCESSES FOR USE
IL278225A (en) Anti SEZ6 antibody drug conjugates and methods of use
EP3675907A4 (en) ANTI-EGFR-DRUG (ADC) ANTIBODY CONJUGATES AND ASSOCIATED USES
EP3755717A4 (en) THERAPEUTIC ANTIBODIES AND ASSOCIATED USES
EP3848049A4 (en) PHARMACEUTICAL COMPOSITION OF ANTI-TIM3 ANTIBODIES AND THEIR USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GAVRILYUK, JULIA

Inventor name: LIU, DAVID

Inventor name: SCHAMMEL, ALEXANDER

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHAMMEL, ALEXANDER

Inventor name: LIU, DAVID

Inventor name: GAVRILYUK, JULIA

INTG Intention to grant announced

Effective date: 20201026

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028800

Country of ref document: HK

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1376848

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20210631

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019003618

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3710485

Country of ref document: PT

Date of ref document: 20210504

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210427

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

GRAT Correction requested after decision to grant or after decision to maintain patent in amended form

Free format text: ORIGINAL CODE: EPIDOSNCDEC

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210505

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 36970

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20210631

Country of ref document: HR

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B8

REG Reference to a national code

Ref country code: SK

Ref legal event code: TB4A

Ref document number: E 36970

Country of ref document: SK

Free format text: CORRECTION TO GAZETTE 10/2021 - SC4A, PAGE 28 32 VESTNIK URADU PRIEMYSELNEHO VLASTNICTVA SR (EUROPSKE PATENTY) 11/2021 - SK DATUM VYDANIA: 9.6.2021:(73) ABBVIE STEMCENTRX LLC, NORTH CHICAGO, IL, US

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210631

Country of ref document: HR

Payment date: 20210511

Year of fee payment: 3

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: NL

Ref legal event code: HC

Owner name: ABBVIE STEMCENTRX LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: ABBVIE STEMCENTRX LLC

Effective date: 20210503

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ABBVIE STEMCENTRX LLC

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210401132

Country of ref document: GR

Effective date: 20210614

Ref country code: NO

Ref legal event code: T2

Effective date: 20210331

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E020873

Country of ref document: EE

Effective date: 20210505

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E053616

Country of ref document: HU

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: ABBVIE STEMCENTRX LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME

Effective date: 20210503

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2867148

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211020

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019003618

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220104

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210631

Country of ref document: HR

Payment date: 20220510

Year of fee payment: 4

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1376848

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230315

Year of fee payment: 5

Ref country code: RS

Payment date: 20230327

Year of fee payment: 5

Ref country code: PL

Payment date: 20230320

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210631

Country of ref document: HR

Payment date: 20230419

Year of fee payment: 5

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230323

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20230426

Year of fee payment: 5

Ref country code: PT

Payment date: 20230426

Year of fee payment: 5

Ref country code: NO

Payment date: 20230425

Year of fee payment: 5

Ref country code: LT

Payment date: 20230515

Year of fee payment: 5

Ref country code: IT

Payment date: 20230515

Year of fee payment: 5

Ref country code: IE

Payment date: 20230425

Year of fee payment: 5

Ref country code: FR

Payment date: 20230412

Year of fee payment: 5

Ref country code: ES

Payment date: 20230607

Year of fee payment: 5

Ref country code: EE

Payment date: 20230413

Year of fee payment: 5

Ref country code: DK

Payment date: 20230426

Year of fee payment: 5

Ref country code: DE

Payment date: 20230412

Year of fee payment: 5

Ref country code: CZ

Payment date: 20230419

Year of fee payment: 5

Ref country code: CY

Payment date: 20230413

Year of fee payment: 5

Ref country code: CH

Payment date: 20230602

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230517

Year of fee payment: 5

Ref country code: SK

Payment date: 20230425

Year of fee payment: 5

Ref country code: SI

Payment date: 20230419

Year of fee payment: 5

Ref country code: LV

Payment date: 20230413

Year of fee payment: 5

Ref country code: IS

Payment date: 20230412

Year of fee payment: 5

Ref country code: HU

Payment date: 20230421

Year of fee payment: 5

Ref country code: HR

Payment date: 20230419

Year of fee payment: 5

Ref country code: GR

Payment date: 20230425

Year of fee payment: 5

Ref country code: FI

Payment date: 20230426

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230413

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230412

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20230510

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230418

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240329

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240319

Year of fee payment: 6

Ref country code: BG

Payment date: 20240321

Year of fee payment: 6

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240415

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240415

Year of fee payment: 6